About Trillium Therapeutics (TSE:TRIL)
Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; and epidermal growth factor receptor antagonist, which is in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on Equity-259.65%
Return on Assets-55.25%
Trillium Therapeutics (TSE:TRIL) Frequently Asked Questions
What is Trillium Therapeutics' stock symbol?
Trillium Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TRIL."
Who are some of Trillium Therapeutics' key competitors?
Some companies that are related to Trillium Therapeutics include Cona Resources (CONA), Aimia (AIM), Storm Resources (SRX), Acasta Enterprises (AEF), Kelt Exploration LNG (RTK), Wesdome Gold Mines (WDO), Inovalis REIT (INO.UN), IBI Group (IBG), Cervus Equipment (CERV), Btb Reit (BTB.UN), Tecsys (TCS), Asanko Gold (AKG), NAPEC (NPC), Stuart Olson (SOX), High Arctic Energy Services (HWO), GDI Integrated Facility Services (GDI), NewCastle Gold (NCA) and Yellow Pages (Y).
Who are Trillium Therapeutics' key executives?
Trillium Therapeutics' management team includes the folowing people:
- Dr. Bjorn Johan Niclas Stiernholm, CEO, Pres & Director
- Mr. James T. Parsons, Chief Financial Officer (Age 53)
- Dr. Robert Uger Ph.D., Chief Scientific Officer
- Dr. Penka Petrova Ph.D., Chief Devel. Officer
- Dr. Eric L. Sievers, Sr. Clinical Advisor
Has Trillium Therapeutics been receiving favorable news coverage?
News headlines about TRIL stock have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern rates the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Trillium Therapeutics earned a media sentiment score of 0.17 on Accern's scale. They also assigned media headlines about the company an impact score of 46.17 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of Trillium Therapeutics?
Shares of TRIL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Trillium Therapeutics' stock price today?
One share of TRIL stock can currently be purchased for approximately C$8.93.
How big of a company is Trillium Therapeutics?
Trillium Therapeutics has a market capitalization of C$124.24 million.
How can I contact Trillium Therapeutics?
Trillium Therapeutics' mailing address is 2488 Dunwin Dr, MISSISSAUGA, ON L5L 1J9, Canada. The company can be reached via phone at +1-416-5950627.
MarketBeat Community Rating for Trillium Therapeutics (TRIL)MarketBeat's community ratings are surveys of what our community members think about Trillium Therapeutics and other stocks. Vote "Outperform" if you believe TRIL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRIL will underperform the S&P 500 over the long term. You may vote once every thirty days.
Trillium Therapeutics (TSE:TRIL) Analyst Ratings History
(Data available from 4/22/2016 forward)
Trillium Therapeutics (TSE:TRIL) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Trillium Therapeutics (TSE TRIL) Insider Trading and Institutional Ownership History
Trillium Therapeutics (TSE TRIL) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|7/7/2017||Gordon Edward Zelko||Director||Buy||93,000||C$0.11||C$10,230.00|
|6/30/2017||Michael Bruno John Fr England||Director||Buy||54,000||C$0.11||C$5,940.00|
|6/15/2017||John Parker Masters||Director||Buy||50,000||C$0.12||C$6,000.00|
|6/6/2017||Michael Bruno John Fr England||Director||Buy||19,000||C$0.11||C$2,090.00|
|5/2/2017||Michael Bruno John Fr England||Director||Buy||100,000||C$0.15||C$15,000.00|
|4/20/2017||Michael Bruno John Fr England||Director||Buy||11,500||C$0.12||C$1,380.00|
|4/19/2017||Michael Bruno John Fr England||Director||Buy||50,000||C$0.12||C$6,000.00|
|4/13/2017||Donald Laughlin Mckinnon||Director||Buy||20,000||C$0.13||C$2,600.00|
|4/10/2017||Michael Bruno John Fr England||Director||Buy||12,000||C$0.10||C$1,200.00|
|3/27/2017||Michael Bruno John Fr England||Director||Buy||5,000||C$0.19||C$950.00|
|3/22/2017||Gordon Edward Zelko||Director||Buy||20,000||C$0.10||C$2,000.00|
|2/17/2017||Michael Bruno John Fr England||Director||Buy||50,000||C$0.12||C$6,000.00|
|2/7/2017||Gordon Edward Zelko||Director||Buy||50,000||C$0.11||C$5,500.00|
|1/31/2017||Michael Bruno John Fr England||Director||Buy||20,000||C$0.11||C$2,200.00|
Trillium Therapeutics (TSE TRIL) News Headlines
Trillium Therapeutics (TSE:TRIL) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Trillium Therapeutics (TSE TRIL) Stock Chart for Sunday, April, 22, 2018